Electroacupuncture alleviates blood-brain barrier disruption and neuroinflammation via astrocytic MC4R in a mouse model of multiple sclerosis.

Researchers studying multiple sclerosis (MS) in mice have discovered how electroacupuncture may protect the brain from inflammation and damage. Multiple sclerosis is a chronic condition where the immune system attacks the protective covering of nerves, leading to communication problems between the brain and body. In this study, scientists used an animal model that mimics MS and applied electroacupuncture at the ST36 acupuncture point (located on the lower leg). The treatment helped protect the blood-brain barrier—a critical protective layer that keeps harmful substances out of the brain—and reduced inflammation in the spinal cord during the peak of the disease. The researchers found that electroacupuncture worked by activating a specific receptor called MC4R on astrocytes, which are star-shaped brain cells that support neurons. When this receptor was activated, it triggered a cascade of protective effects by blocking inflammatory signaling pathways (MAPK and NF-κB). To confirm these findings, the team used various methods: they gave mice drugs that either mimicked or blocked the receptor's activity, and they used genetic techniques to turn the receptor on or off specifically in astrocytes. Each experiment confirmed that MC4R was essential for the protective effects. While this research was conducted in mice and hasn't yet been tested in human MS patients, it provides valuable scientific evidence for how acupuncture might work at the cellular level to reduce neuroinflammation. If you're considering acupuncture for any neurological condition, consult with a licensed acupuncturist who has experience in your specific health concern.

This preclinical study investigated electroacupuncture's mechanisms in experimental autoimmune encephalomyelitis (EAE), a validated MS model. EA at ST36 during peak EAE disease significantly reduced blood-brain barrier disruption and neuroinflammation. Mechanistic investigations revealed EA upregulated α-melanocyte-stimulating hormone (α-MSH) and melanocortin-4 receptor (MC4R) expression specifically in spinal astrocytes. Pharmacological validation using MC4R agonist RO27-3225 reproduced EA's therapeutic effects, while antagonist TCMCB07 attenuated benefits. Astrocyte-specific MC4R silencing via AAV confirmed cell-type specificity. RNA-sequencing and Western blot analyses demonstrated EA's neuroprotection occurs through MC4R-mediated inhibition of MAPK and NF-κB signaling pathways. In vitro studies with MC4R-overexpressing astrocytes corroborated the MAPK/NF-κB mechanism. Clinical significance: This study provides molecular evidence for EA's anti-neuroinflammatory effects via astrocytic MC4R signaling, supporting EA as adjuvant therapy for MS and potentially other neuroinflammatory conditions. The identified pathway offers a specific therapeutic target and validates traditional point selection for neurological disorders.